Saturday 17 October 2026
Export WOK’s income statement to Excel — free account
WORK Medical Technology Group LTD
WOK Healthcare Medical Devices
WORK Medical Technology Group LTD’s revenue for fiscal 2025 (year ended September 2025) was $9.8 million, down 14.4% from fiscal 2024. Insiders bought in the last twelve months.
1.09
0.25
−18.66%
Follow WOK
| Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 7 | 3 | 5 |
Altman Z-Score |
— | — | — | 19,424.02 | 1,088.09 |
Altman Z″-Score (non-manufacturers) |
2.85 | 2.80 | 2.45 | 0.75 | 3.51 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (1.89) | (1.69) | (2.31) | (1.72) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | (1.80) | (50.04) |
EV/FCF |
0.00 | 0.00 | 0.00 | (0.44) | (0.24) |
Quick Ratio |
0.33 | 0.33 | 0.49 | 0.56 | 1.29 |
Current Ratio |
1.17 | 1.17 | 1.17 | 1.03 | 1.71 |
Net Debt/EBITDA |
(0.94) | 1.33 | 3.57 | (2.42) | (1.46) |
Debt/Assets |
0.00% | 23.39% | 29.51% | 36.75% | 19.28% |
Debt/Equity |
0.00 | 0.53 | 0.80 | 0.83 | 0.30 |
Asset Turnover |
0.00 | 0.77 | 0.49 | 0.35 | 0.28 |
Operating CF/Net income |
0.00 | (2.61) | 19.73 | 0.64 | (5.82) |
Capex/Depreciation |
— | (0.43) | (0.36) | (6.43) | (0.93) |
Interest Coverage |
2.34 | 1.82 | 1.05 | (7.25) | (4.96) |
| 0.00% | 8.36% | 1.01% | (25.82%) | (5.76%) | |
| 0.00% | 3.39% | 0.40% | (10.55%) | (3.09%) | |
ROIC |
4.93% | 2.43% | 1.42% | (11.27%) | (6.65%) |
Return on Tangible Assets |
8.45% | 8.45% | 1.14% | (29.06%) | (5.62%) |
Average Days of Receivables |
73.96 | 73.96 | 203.67 | 138.18 | 422.57 |
Research and Development Expense of Revenue |
0.00% | 0.93% | 2.22% | 2.63% | 4.42% |
Selling, General and Administrative Expense of Revenue |
18.25% | 18.25% | 25.28% | 57.46% | 44.73% |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.03 | 0.03 | 0.03 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 1.58 | 1.09 | 90.53 | 33.98 |
Operating CF per Share |
— | (0.18) | 0.18 | (17.53) | 21.55 |
Capex per Share |
— | (0.11) | (0.05) | (71.31) | (2.97) |
Free Cash Flow per Share |
— | (0.29) | 0.13 | (88.84) | 18.58 |
Cash per Share |
0.00 | 0.06 | 0.13 | 54.74 | 14.11 |
Shareholders Equity per Share |
0.00 | 0.90 | 0.88 | 126.44 | 73.03 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.90 | 0.88 | 126.44 | 73.03 |
Free Cash Flow |
— | (3.67) | 1.63 | (11.29) | 5.38 |
Working Capital |
2.35 | 2.35 | 3.23 | 0.65 | 8.48 |
Capital Expenditures |
— | (1.41) | (0.58) | (9.06) | (0.86) |
Net Current Asset Value |
2.26 | 2.26 | 3.18 | 0.65 | 8.46 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.07 | 0.04 | 0.79 | 0.09 |
| Other line items | |||||
Depreciation/Fixed assets |
0.00 | 0.41 | 0.24 | 0.12 | 0.09 |
Cash ROIC |
0.00% | (20.46%) | 7.58% | (31.06%) | 17.02% |
Accounts Receivable Turnover |
0.00 | 4.94 | 2.35 | 1.93 | 1.25 |
Accounts Payable Turnover |
0.00 | 0.00 | 2.63 | 3.16 | 4.66 |
Inventory Turnover |
0.00 | 3.51 | 2.10 | 2.21 | 2.66 |
Average Days of Payables |
0.00 | 76.44 | 153.46 | 63.26 | 83.89 |
Days of Inventory on Hand |
104.02 | 104.02 | 178.96 | 134.54 | 119.44 |
Average Receivables |
— | 3.99 | 5.78 | 5.96 | 7.88 |
Average Payables |
— | — | 3.58 | 2.73 | 1.61 |
Average Inventory |
— | 4.36 | 4.49 | 3.90 | 2.82 |
Average Assets |
— | 25.54 | 27.75 | 33.10 | 34.70 |
Average Common Equity |
— | 10.35 | 11.09 | 13.53 | 18.62 |
Columns are period end dates